Background
Materials and methods
Clinical samples and cell lines
Immunohistochemistry (IHC) analysis
Western blot analysis
GLYR1 exon13 mutation detection
Small interfering RNA (siRNA) and short hairpin RNA (shRNA) transfection
RNA extraction and qRT-PCR
Co-immunoprecipitation (co-IP)
Immunofluorescence and co-localization
Drug treatment
Flow cytometric analysis
Hoechst 33258 staining assay
Cell counting kit-8 (CCK-8) and colony formation assays
Statistical analysis
Results
GLYR1 is downregulated in MSI CRC
No.of cases | Low | Medium | High | χ2 value | P-value | |
---|---|---|---|---|---|---|
Frequency | 221 (100%) | 44 (19.9%) | 64 (29.0%) | 113 (51.1%) | ||
Age | ||||||
Younger (< 60 years) | 118 (53.4%) | 24 (20.3%) | 36 (30.5%) | 58 (49.2%) | 0.427 | 0.808 |
Older (> = 60 years)) | 103 (46.6%) | 20 (19.4%) | 28 (27.2%) | 55 (53.4%) | ||
Gender | ||||||
Male | 135 (61.1%) | 26 (19.3%) | 42 (31.1%) | 67 (49.6%) | 0.781 | 0.677 |
Female | 86 (38.9%) | 18 (20.9%) | 22 (25.6%) | 46 (53.5%) | ||
Position | ||||||
Colon | 150 (67.9%) | 38 (25.3%) | 45 (30.0%) | 67 (44.7%) | 10.890 | 0.004 |
Rectum | 71 (32.1%) | 6 (8.4%) | 19 (26.8%) | 46 (64.8%) | ||
Tumor sise (maximum diameter) | ||||||
< 5 cm | 106 (48.0%) | 8 (7.5%) | 34 (32.1%) | 64 (60.4%) | 19.726 | < 0.001 |
> =5 cm | 115 (52.0%) | 36 (31.3%) | 30 (26.1%) | 49 (42.6%) | ||
Tumor grade (diffrentiation) | ||||||
G1 | 27 (12.2%) | 1 (4.8%) | 6 (28.6%) | 14 (66.7%) | 33.570 | < 0.001 |
G2 | 173 (78.3%) | 27 (15.6%) | 51 (29.5%) | 95 (54.9%) | ||
G3 | 21 (9.5%) | 16 (59.3%) | 7 (25.9%) | 4 (14.8%) | ||
Invasive depth | ||||||
Submucosal | 14 (6.4%) | 0 (0.0%) | 6 (42.9%) | 8 (57.1%) | 9.586 | 0.143 |
Myometrium | 21 (9.5%) | 2 (9.5%) | 6 (28.6%) | 13 (61.9%) | ||
Subserosal | 92 (41.6%) | 16 (17.4%) | 26 (28.3%) | 50 (54.3%) | ||
Break the serosa | 94 (42.5%) | 26 (27.7%) | 26 (27.7%) | 42 (44.6%) | ||
Mucinous component | ||||||
Absent | 165 (74.7%) | 21 (12.7%) | 52 (31.5%) | 92 (55.8%) | 21.066 | < 0.001 |
Present | 56 (25.3%) | 23 (41.1%) | 12 (21.4%) | 21 (37.5%) | ||
Microsatellite instability | ||||||
MSS | 164 (74.2%) | 7 (4.3%) | 48 (29.3%) | 109 (66.4%) | 107.823 | < 0.001 |
MSI-L | 6 (2.7%) | 4 (66.6%) | 1 (16.7%) | 1 (16.7%) | ||
MSI-H | 51 (23.1%) | 33 (64.7%) | 15 (29.4%) | 3 (5.9%) | ||
Lymphatic metastasis | ||||||
Negative | 131 (59.3%) | 27 (20.6%) | 41 (31.3%) | 63 (48.1%) | 1.268 | 0.530 |
Positive | 90 (40.7%) | 17 (18.9%) | 23 (25.6%) | 50 (55.5%) |